What's Hot
View all perspectives
Mithu Maheswaranathan, MD
1 year ago
Latest in Lupus Treatment at #ACR23
• Dr. Dall’Era & Dr. Furie
• Approach to Lupus Nephritis 🫘
• Treating Non-Renal SLE / Skin
#Lupus #RheumTwitter #Rheumatology https://t.co/sagVipdNJe
Mike Putman EBRheum
1 year ago
Great time at the Knowledge Bowl! Huge thanks to my co-hosts, judges, and amazing #ACR23 staff
Congrats to the IGGenerals for taking home the big prize and kudos to ANA 1:40 for the much deserved spirit award! https://t.co/u7bFeQjXeY
Aurelie Najm
1 year ago
ARTIC REWIND RCT 3 yrs csDMARD withdrawal
38% 3yrs csDMARDs free remission vs. 80% stable dose gpe
75% recovery after restart
Rx progression 19% in half dose gpe
More use bioDMARDs (18%) & GCs (50%) withdraw gpe
Trends towards lower infections
@RheumNow #ACR23 #ACRBest https://t.co/jhOINV7LLS
Janet Pope
1 year ago
Low dose #prednisone has (bad) brain effects. An argument to use steroid sparing drugs in #PMR @philseo @ACRheum @RheumNow #ACR23 THINK about steroid sparing Rx in ?all pts with #PMR #Great #debate https://t.co/usQJRNUN8B
Robert B Chao, MD
1 year ago
Anterior uveitis incidence across different axSpA treatments
Large review and meta-analysis on TNFi, IL-17i, JAKi
Immunomodulatory therapy protective against uveitis flare
Greatest in TNFi and JAKi
@RheumNow #ACR23 Abs# 2550 https://t.co/l3BTL3GuRt
debaditya_roy
1 year ago
#Lupus #ACR23🦋
🌍A wonderful session unraveling scientific breakthroughs of #CAR T cell therapy
🔥Promising step towards future in revolutionizing Lupus T/t💡📑
💡Keeps efficacy of other vaccines intact!
Follow this thread showcasing other imp findings
#ACRambassador
1/2 https://t.co/aNFTmJiH0X
Laurent ARNAUD
1 year ago
✅ Michelle Petri in the VERY FULL #ACR23 early session about #lupus:
BEFORE stepping-up with biologics, ask the key questions:
-Are you using proton-pump inhibitors (Drug-induced SCLE)
-Can I see your sunscreen?
-Can I see your hat?
-Are you smoking?
-Any HCQ blood levels? https://t.co/s73FqyjLOn
debaditya_roy
1 year ago
#CAR T cells #ACR23
🔥Back to back Sessions on one of the most avidly researched area in Rheum!
💡Check out these slides to understand:
☣️Toxicities and Limitations of CAR T therapy
🆕 Novel CAR designs
⚡️CAR cell sources
❓Research Questions to ponder!
#ACRambassador https://t.co/6sOn4rjqY3
Today was a big day for the Plenaries, Curbside Consults, ACR Business meeting (and induction of our new ACR President Dr. Deborah Desir) and Late-Breaking Posters. Our hot-button reporters have compiled these #ACRbest abstracts for you! (November 14, 2023 at #ACR23)
David Liew drdavidliew
1 year ago
Toxicities and limitations of CAR therapy:
the other side of its incredibly exciting, boundless potential
@Michel_Sadelain @MSKCancerCenter #ACR23 @RheumNow https://t.co/L1UIqqlOdC
Jeffrey Sparks MD MMSc jeffsparks
1 year ago
Congrats to Dr Kaitlin McCarter for her #ACR23 investigating predictors and mortality of pre-existing RA flare after immune checkpoint inhibitor.
46% flared
Seropositive- OR 2.0
NO association with mortality
-ICIs are safe to use in RA
-Flares are not a proxy of efficacy https://t.co/eoy0FJb1nA
Poster Hall